Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on October 5, 2021. The report discloses significant changes in corporate governance and management, specifically the departure of the interim Principal Accounting Officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure: Punit Dhillon tendered his resignation as interim Principal Accounting Officer effective October 4, 2021.
- Appointment: Kaitlyn Arsenault was appointed Chief Financial Officer (CFO) effective October 4, 2021.
- Compensation Package:
- Base Salary: $300,000 annually.
- Bonus: Discretionary annual bonus up to 35% of base salary based on milestones.
- Equity: Grant of options to purchase 1,600,000 shares of common stock at an exercise price of $0.09 per share.
- Vesting Schedule: 10% vested immediately; remaining 90% vests in semi-annual installments over four years.
- Severance: Entitled to six months' base salary upon termination without Cause, Death, or Disability.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the at-will nature of the new CFO's employment, subject to specific severance terms defined in the employment agreement.
Investor Verification Checklist
- Verify the full text of the Executive Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Death," and "Disability."
- Confirm the impact of the 1,600,000 share option grant on existing shareholder dilution.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor subsequent filings for the appointment of a new Principal Accounting Officer to replace the interim role vacated by Punit Dhillon.